Acrivon Therapeutics, Inc. ACRV
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is an oncology drug developer. Its lead program, ACR-368 (prexasertib), is in Phase 2 for endometrial cancer.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ACR-368 | endometrial cancer | small molecule | Phase 2 |
| ACR-2316 | solid tumors (WEE1/PKMYT1) | small molecule | Phase 1 |
| CDK11 program | oncology | small molecule | Pre-clinical |
Recent results and decisions
- Aug 12, 2026started ACR-2316 advanced into randomized dose expansion (120 mg and 160 mg QD, 3d on/4d off) of the Phase 1/2 study.
ACR-2316 advanced into the randomized dose expansion stage of the Phase 1/2 study, supported by observed favorable safety profile and durable antitumor activity.
Filing - May 13, 2026started Arm 4 (single-agent ACR-368, all-comer serous EC) enrollment and dosing recently initiated.
Arm 4 enrollment and dosing was recently initiated, investigating single agent ACR-368 without ULDG, in the same “serous all comer” subject population as Arm 3
Filing - Mar 19, 2026positive ESGO late-breaker recap: serous EC cORR 52% (N=23) vs 22% (N=37) non-serous in subjects with <=2 prior lines (previously reported in Jan 2026).
Consistent with higher BM levels in serous versus non-serous EC, an interim analysis across both OncoSignature-positive (BM+) and BM- serous EC subjects showed a cORR of 52% (N = 23) versus 22% (N = 37) in non-serous EC subjects
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.